GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » EV-to-EBIT

Recordati SpA (Recordati SpA) EV-to-EBIT : 20.18 (As of May. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Recordati SpA's Enterprise Value is $12,506 Mil. Recordati SpA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $620 Mil. Therefore, Recordati SpA's EV-to-EBIT for today is 20.18.

The historical rank and industry rank for Recordati SpA's EV-to-EBIT or its related term are showing as below:

RCDTF' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.04   Med: 19.2   Max: 28.73
Current: 20.21

During the past 13 years, the highest EV-to-EBIT of Recordati SpA was 28.73. The lowest was 11.04. And the median was 19.20.

RCDTF's EV-to-EBIT is ranked worse than
58.33% of 672 companies
in the Drug Manufacturers industry
Industry Median: 16.985 vs RCDTF: 20.21

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Recordati SpA's Enterprise Value for the quarter that ended in Dec. 2023 was $11,207 Mil. Recordati SpA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $620 Mil. Recordati SpA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 5.53%.


Recordati SpA EV-to-EBIT Historical Data

The historical data trend for Recordati SpA's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA EV-to-EBIT Chart

Recordati SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.83 21.61 25.75 21.66 20.59

Recordati SpA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.50 18.87 19.63 20.59 -

Competitive Comparison of Recordati SpA's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Recordati SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recordati SpA's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Recordati SpA's EV-to-EBIT falls into.



Recordati SpA EV-to-EBIT Calculation

Recordati SpA's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=12505.751/619.657
=20.18

Recordati SpA's current Enterprise Value is $12,506 Mil.
Recordati SpA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $620 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Recordati SpA  (OTCPK:RCDTF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Recordati SpA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=619.657/11207.015
=5.53 %

Recordati SpA's Enterprise Value for the quarter that ended in Dec. 2023 was $11,207 Mil.
Recordati SpA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $620 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Recordati SpA EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Recordati SpA's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Recordati SpA (Recordati SpA) Business Description

Traded in Other Exchanges
Address
Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire 03-09-2020